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Summary The purpose of this study was to determine the effect of the first rat monoclonal antibody (MAb
ICR62) to the epidermal growth factor receptor (EGFR) in a phase I clinical trial in patients with unresectable
squamous cell carcinomas. This antibody effectively blocks the binding of EGF, transforming growth factor
(TGF)-oc and HB-EGF to the EGFR, inhibits the growth in vitro of tumour cell lines which overexpress the
EGFR and eradicates such tumours when grown as xenografts in athymic mice. Eleven patients with squamous
cell carcinoma of the head and neck and nine patients with squamous cell carcinoma of the lung, whose
tumours expressed EGFR, were recruited. Groups of three patients were treated with 2.5 mg, 10 mg, 20 mg or
40 mg of ICR62 and a further eight patients received 100 mg. All patients were evaluated for toxicity using
WHO criteria. Patients' sera were tested for the clearance of MAb ICR62 and the development ofhuman anti-
rat antibodies (HARA). No serious (WHO Grade III-IV) toxicity was observed in patients treated with up to
100 mg of antibody ICR62. Antibody ICR62 could be detected at 4 h and 24 h in the sera of patients treated
with 40 mg or 100 mg of ICR62. Only 4/20 patients showed HARA responses (one at 20 mg, one at 40 mg and
two at 100 mg doses) and of these only the former two were anti-idiotypic responses. In four patients receiving
doses of ICR62 at 40 mg or greater, biopsies were obtained from metastatic lesions 24 h later and examined for
the localisation of ICR62 using anti-rat antibody reagent. In these patients we showed the localisation of MAb
ICR62 to the membranes of tumour cells; this appeared to be more prominent at the higher dose of 100 mg.
On the basis of these data we conclude that MAb ICR62 can be administered safely to patients with squamous
cell carcinomas and that it can localise efficiently to metastases even at relatively low doses.
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It is becoming increasingly evident that alterations in the level
of expression of growth factors and their receptors may play
an important role in the pathogenesis of human malignancies
(Goustin et al., 1986; Aaronson, 1991; Cross and Dexter,
1991; Waterfield, 1991; Pusztai et al., 1993; Mendelsohn and
Lippman, 1993; Nicolson, 1993). Of the systems studied, it is
clear that the aberrant expression of the epidermal growth
factor (EGF) receptor system is particularly important in the
development of certain types of human malignancy
(Thompson and Gill, 1985; Ozanne et al., 1986; Gullick,
1991; Harris, 1994; Modjtahedi and Dean, 1994). The human
EGF receptor is a 170 kDa transmembrane tyrosine kinase
that transmits the mitogenic actions of the EGF family of
ligands. This includes EGF, transforming growth factor
(TGF)-a, amphiregulin, HB-EGF, and betacellulin (Cohen,
1962; Todaro et al., 1976; Das et al., 1977; Shoyab et al.,
1989; Higashiyama et al., 1991; Shing et al., 1993; Carpenter,
1987).
Overexpression of the EGFR accompanied by production
of one or more of its ligands has been reported in a wide
range of human malignancies, including cancer of the
bladder, brain, head and neck, pancreas, lung, breast and
ovary (Cowley et al., 1984; Ozanne et al., 1986; Neal et al.,
1990; Gullick, 1991; Modjtahedi and Dean, 1994). This in
turn has been associated with poor survival in many of these
patients (for review see Modjtahedi and Dean, 1994). Recent
studies have also indicated that the growth of tumours
overexpressing the EGF receptor can be stimulated by its
ligands in several ways, e.g. via autocrine, paracrine or
juxtacrine modes (Sporn and Roberts, 1985; Derynck, 1992;
Modjtahedi and Dean, 1994). However, since the ligand-
induced activation of these cells occurs primarily via
receptors on the cell surface rather than intracellularly, this
system may form a suitable target for monoclonal antibody-
directed therapy (Van de Vijvert et al., 1991; Baselga and
Mendelsohn, 1994; Modjtahedi and Dean, 1994).
We have reported recently the production and character-
isation of a number of rat MAbs directed against the
extracellular domain of the EGFR using as immunogens the
human head and neck tumour cell line HN5, breast
carcinoma cell line MDA-MB 468 or the vulval carcinoma
cell line A431, all of which overexpress the human EGFR
(see Modjtahedi and Dean, 1994 for details). Our aim was to
obtain a diverse population of antibodies that bound to
distinct epitopes on the EGFR and which were of different
isotype in order to select the best MAb or combination of
MAbs for therapeutic and diagnostic use. Ofthese, the IgG2b
MAb ICR62 was prominent in that it (a) effectively blocks
the binding of EGF, TGF-ai, and HB-EGF to EGFR; (b)
inhibits the growth of EGFR-overexpressing tumour cell lines
in vitro (Modjtahedi et al., 1993a; Modjtahedi and Dean
1995); and (c) was the most effective antibody in our MAb
library for eradicating such tumours in athymic mice
(Modjtahedi et al., 1993b; Dean et al., 1994). We have also
reported recently that antibodies to the EGFR that inhibit
the growth of EGFR-overexpressing tumours do so by
inducing terminal differentiation and that a further ther-
apeutic effect may be obtained via immunological mechan-
isms with rat IgG2b MAbs such as ICR62 (Modjtahedi et al.,
1994).
For these reasons we have selected MAb ICR62 for a
phase I clinical study in patients with unresectable squamous
cell carcinoma of the head and neck or lung. These tumour
types commonly overexpress the EGFR. With only limited
quantities of antibody available, the aims of this initial study
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1995were to (a) monitor the toxicity of ICR62 in the dose range
of 2.5-100 mg, (b) investigate the localisation of MAb
ICR62 to tumour cells in metastatic lesions, (c) determine the
dose of ICR62 necessary to achieve circulating ICR62 in the
blood and (d) assay for human anti-rat antibody (HARA)
responses. This communication describes the results of the
first phase I clinical study using a rat MAb to the EGFR.
Materials and methods
Preparation of MAb ICR62 for clinical use
All antibody for clinical use was prepared according to the
guidelines prepared by the Cancer Research Campaign
(CRC)-Medical Research Council (MRC) Joint Committee.
Hybridoma cells were grown in Dulbecco's modified Eagle
medium (DMEM) containing 3% or 5% fetal calf serum of
North American origin and antibiotics as described pre-
viously (Modjtahedi et al., 1993a), in either a Verax Type I
Bioreactor or as bulk cultures in roller bottles. Supernatants
were harvested under aseptic conditions and then precipitated
with ammonium sulphate at 45% saturation. Using
autoclaved reagents, column packings and containers, the
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precipitates were dissolved in water and dialysed against
0.0175 M phosphate buffer pH 6.6. After centrifugation in a
Beckman 45Ti rotor at 30 000 g to remove insoluble material,
the dialysate was fractionated by passage through a column
of Whatman DE52 cellulose equilibrated with and eluted
with 0.0175 M phosphate buffer pH 6.6. The flow through
fractions containing the purified (>95% MAb) ICR62 were
bulked and dialysed against five changes of sterile phosphate-
buffered saline (PBS). After filter sterilisation the preparation
was aliquoted, frozen and stored at -20°C until use.
Patient details
Patients were considered eligible for inclusion in this trial
who had (i) inoperable histologically or cytologically
confirmed diagnosis of squamous cell carcinoma of the lung
or head and neck, (ii) immunohistochemically proven tumour
expression of the EGFR (iii) an ECOG performance status of
0-2, (iv) no known history of allergy or atopy, (v) no
immunological therapy within the previous 4 weeks, (vi) no
significant abnormalities of renal, hepatic or bone marrow
function (haemoglobin>10 g dl- , white count>3 x 109 1 -1,
platelet> 120, creatinine< 130, liver enzymes and biliru-
Table I Patient data
PS weight HARA
Patient no. Sex Site Age (kg) Previous treatment ICR62 dose CTC toxicity (grade) response
1 M HN 58 1 S, R, C 2.5 mg - -
F
F
M
HN
HN
HN
74
51
49
46
2
66
1
39
1
60
M HN 57 1
58
M HN 46 2
43
F L 66 1
55
M L 61 1
71
M L 56 1
61
F HN 75 2
50
M HN 45 1
65
F L 68 1
43
M L 70 1
84
M HN 79 1
46
M L 65 1
55
M HN 37 1
79
M L 67 1
63
M HN 44 1
75
F L 54 0
61
F L 71 1
96
g; HN, head and nack; S, surgery; R, radiotherapy; C, chemotherapy; I, immunotherapy; PS, performance status; HARA, human
anti-rat antibody; ID, idiotypic.
2
3
4
5
6
7
8
9
S, R
R, C
S, 1, C
S
R
C
S, R, C,
1, S, R, C
R, C, R
R, C,
S, R, I, C
S
R, I
R, I, C
C, R
S, R, C
S, R, C
(also breast 10)
2.5 mg
2.5 mg
10 mg
10 mg
10 mg
20 mg
20 mg
20 mg
40 mg
40 mg
40 mg
100 mg
100 mg
100 mg
100 mg
100 mg
100 mg
100 mg
100 mg
Fever (I)
Fever (I)
BP (II)
ALT (I)
Fever (I)
BP (I)
Rigor (I)
Rigor (I)
Fever (II)
N&V (II)
BP (I)
Rigor (II)
Fever (II)
Chest pain (I)
Chest pain (I)
Fever (I)
Creatinine (I)
Fever
ALT (I)
Rigor (I)
Fever (I)
ALT (I)
Fever (I)
Fever (I)
Rigor (I)
BP (I)
BP (I)
Fever (I)
Rigor (I)
Rigor (II)
Fever (I)
BP (I)
Rigor (I)
Fever (I)
Fever (I)
Rigor (I)
Rigor (I)
Nausea (I)
Fever (II)
Rigor (I)
Fever (I)
Rigor (II)
N&V (II)
10
11
12
13
14
15
16
17
18
19
20
ANTI (ID
Anti-ID
+
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bin< x 2 normal). The trial had approval from the CRC
Phasel/II Clinical Trials Committee and the Royal Marsden
Hospital Ethical Committee and all participants had given
written informed consent. Patients were skin tested (10 pg
ICR62 intradermally) 1 h before antibody was administered
and no patient was found to give an adverse reaction.
Antibody in PBS pH 7.4 was given intravenously as a
single bolus injection over a period of 30-60 min. Groups of
three patients were treated with 2.5, 10, 20, or 40 mg of
a
ICR62 and a further eight patients were given 100 mg (Table
I). All patients were evaluated for toxicity using standard
WHO criteria. Blood samples were taken before and at
intervals after dosing with ICR62 so that levels of MAb
ICR62 in circulation could be measured and sera tested for
the presence of HARA. In six patients given antibody doses
of 40 mg or 100 mg, biopsies were taken from accessible
metastatic lesions 24 h following dosing and examined for the
localisation of ICR62.
--w* Prebleed
-o- 4h
-4-- + 24 h
--o- day8
-&- day 28
-/&- ICR62 Standard
6
E
(3
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0
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w LU
Dilution of patient serum
Figure 1 Serum levels of MAb ICR62 following dosing with (a) 20mg (patient 8) (b) 40mg (patient 10) (c) 100mg (patient 13) of
antibody. Free antibody was determined by inhibition of binding of [12 EGF to EJ cells by doubling dilutions of patients' sera or
an ICR62 standard (starting concentration 50tgml-1).
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__Determination ofserum levels ofICR62
The amount of free MAb ICR62 present in serum was
determined by its ability to inhibit the binding of ['251] EGF
to the human bladder carcinoma cell line (EJ) as described
previously (Modjtahedi et al., 1993a). Doubling dilutions of
serum (50 jl) were mixed with an equal volume of [1251] EGF
(4 x 104 c.p.m.). Standards containing known concentrations
of ICR62 were set up in the same way. Aliquots of 90 ,l of
each mixture were then transferred to monolayers of EJ cells
grown to confluency in 96-well plates. After incubation for
1 h on ice the cells were washed three times, then lysed in 1 M
sodium hydroxide containing 1% sarkosyl and the bound
radioactivity was determined in a Hydragamma spectrometer
(Oakfield Instruments, Oxford).
Immunohistochemistry
All immunohistochemical studies were performed by the
indirect method using sheep antibodies to rat F(ab')2
conjugated to horseradish peroxidase (Amersham Interna-
tional).
To determine expression of EGFR, tumour biopsies were
snap frozen in liquid nitrogen then mounted in OCT medium
and sections of 5 gIM thickness cut. One section was stained
with haematoxylin and eosin (H&E) for histology. A second
sample was fixed in acetone at 4'C for 10 min, then after
washing briefly in PBS the section was incubated with MAb
ICR62 (100 ig ml-') for 1 h. Following washing in PBS for
5 min, the sections were incubated with a 1:100 dilution of
secondary antibody [sheep anti-rat F(ab')2 conjugated to
horse radish peroxidase, Amersham] for 45 min. Peroxidase
staining was demonstrated by incubating the sections for
10 min in a solution containing 0.05% diaminobenzidine
(Sigma), 0.1% hydrogen peroxide (Merck) and 0.07%
imidazole (Merck). After washing in running tap water for
5 min, the sections were counterstained in Mayer's haema-
toxylin (HD Suppliers) for 30 s. Finally the sections were
dehydrated, cleared and mounted.
To assay for the localisation of MAb ICR62 to tumours
in patients, biopsies were taken from an accessible
metastatic site 24 h after antibody dosing. Serial sections
were cut and stained with secondary antibody alone or
ICR62 followed by the secondary antibody. This technique
enabled us to determine the proportion of EGFR-
expressing cells that had bound administered ICR62
(Modjtahedi et al., 1994).
Assay for human anti-rat (HARA) response
We have investigated the immunogenicity of MAb ICR62 by
determining if human anti-rat antibodies were present in the
sera of patients given different doses of ICR62. Also, we
have investigated if the human anti-rat response included
anti-idiotypic antibodies by determining if the antibodies in
the patient's sera bound to scFv fragments of ICR62.
Polyvinyl chloride 96-well plates (Dynatech Labs, VA,
USA), were coated with rat antibody by incubation
overnight at 4°C with 50 4ul per well of a stock solution
(10 jug 5 ml-' of PBS) of ICR62, ICR62 Fab (Modjtahedi et
al., 1995), or ICR62 scFv (C Dean et al., manuscript in
preparation). The plates were washed three times with PBS
containing 0.5% bovine serum albumin (BSA) and then
incubated for 2 h with 200 ,ul per well of PBS-0.5% BSA to
block the remaining sites. After a further three washes with
PBS containing 0.5% BSA, doubling dilutions of the
patient's sera in PBS-0.5% BSA were added in duplicate
to the wells and the plates were incubated for 1 h at
ambient temperature. After washing the plates three times
with PBS-0.5% BSA, human antibodies bound to ICR62
or its fragments were detected by the addition of 251I-labelled
rabbit anti-human F(ab')2. After incubation for 1 h at
ambient temperature, the plates were washed three times
with PBS - 0.5% BSA and then cut into individual wells
and the bound radioactivity determined.
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Results
Patient details and clinical observations
Twenty patients, 11 with head and neck cancers and nine
with lung cancers were recruited. Patient details are
summarised in Table I. Following intravenous injections of
the antibody, 18 patients exhibited mild (WHO grade I-II)
rigors and fever or hypotension (Table I). Symptoms were
controlled by hydrocortisone (100 mg) and Piriton (10 mg).
In no case were any severe toxicities (Grade III-IV)
observed. None of the patients reported any untoward
effects of their treatment during the follow-up period.
Serum levels of ICR62
No free antibody was detected in the sera, sampled at 4 h or
24 h post dosing, of patients given 20 mg or less of ICR62
(Figure la). However, MAb ICR62 could be detected in the
sera of patients following doses of 40 mg or 100 mg (Figure
lb and lc). In addition, the level of ICR62 remaining in
circulation was found to be highest in the patients receiving
100 mg of ICR62 (Figure 1). In one such patient (number
13), MAb ICR62 was readily detectable in the serum at a
a
b
Figure 2 Localisation of MAb ICR62 to metastatic lesions. (a)
Frozen section of a squamous cell carcinoma from patient 12
taken 24h following dosing with 40mg of ICR62 and stained with
peroxidase-conjugated secondary antibody only. The ICR62
antibody has localised to a peripheral rim of the epithelium
about 1 -3 cells deep. (b) Consecutive section from the same
block stained with ICR62 followed by secondary antibody
showing that all cells of the epithelial component express
EGFR. Magnification x 26.Anti-EGFR MAb ICR62 in phase I clinical Wial
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Figure 3 Localisation of MAb ICR62 to metastatic lesions. Frozen section of a squamous carcinoma from a metastatic lesion from
patient 18 taken 24h following dosing with 100mg of ICR62 and stained with peroxidase-conjugated secondary antibody only (a),
(b). Consecutive section from the same block stained with ICR62 and the peroxidase-conjugated secondary antibody showing that
all epithelial cells express the EGFR (c), (d). Magnification (a) and (c) ( x 26), (b) and (d) different fields in (a) and (c) at x 130.
concentration of about 8 ,ug ml-', 3 days following admin-
istration (Figure ic). No free MAb could be detected in the
serum 7 days post ICR62 treatment in any patient.
Injected ICR62 binds to the EGFR on tumour cell
membranes
Having shown that MAb ICR62 was in circulation at 24 h in
patients given doses of 40 mg, we subsequently investigated
whether in such patients MAb ICR62 was localised to the
tumour. Biopsies of metastatic lesions were taken from six
patients, 24 h after ICR62 dosing. Two of the biopsies
(patients 17 and 19) were found to consist largely of necrotic
material and were discarded, but four (patients 10, 12, 18 and
20) yielded well-defined samples containing viable tumour.
The sections illustrated in Figure 2a show that 24 h after
treatment of patient 12 with 40 mg of ICR62, the antibody
had localised to the membranes of tumour cells around the
periphery of the epithelial cell islands in the metastatic site.
When a sequential section was stained with ICR62 before the
addition of the sheep anti-rat reagent, it was found that all
cells, including those in the interior of the epithelial cell
islands expressed the EGFR (Figure 2b).
However, when frozen sections of biopsies obtained
from metastases of patients treated with 100 mg of ICR62
were examined, it was clear that the MAb had penetrated
further into the epithelial component of the metastatic
lesions with a greater proportion of EGFR-positive cells
having bound administered ICR62 (e.g. Figures 3a and 3c
or 3b and 3d).
Development of human antibodies to ICR62
Of the 20 patients treated with ICR62, HARA were detected
in the sera of four patients (numbers 9, 11, 16 and 19; see
Table I). Of these, only two patients given 20 mg (no. 9) or
40 mg (no. 11) produced anti-idiotypic antibodies that bound
to scFv ICR62 (Figure 4). Sera from two out of eight patients
treated with 100 mg of ICR62 (patients 16 and 19) contained
antibodies directed against determinants on the constant
region since they bound to the Fab fragment and intact
antibody but not to the ICR62 scFv (Table I, Figure 5). In
one patient (no. 12), the results obtained with the serum
taken before treatment indicated that antibodies that bound
to rat IgG were present in the sera before ICR62 was
administered. It is unknown whether binding was specific or
due to the presence of cross-reactive autoantibodies.
Discussion
Overexpression of the EGFR accompanied by production of
the EGF family of ligands has been found to occur in a wide
range of human malignancies and this phenomenon has been
correlated with a poorer prognosis in these patients (for
review see Gullick, 1991; Modjtahedi and Dean, 1994).
During the past 14 years a number of mouse monoclonal
antibodies have been raised against epitopes on the external
domain of the human EGFR and these have been used not
only to investigate growth factor-receptor interaction and
the mechanism(s) of activation of the EGF receptor system
a
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Figure 4 Development ofhuman anti-rat antibodies in the serum
ofpatient number 9 following injection of 20mg ICR62 shown by
binding to intact ICR62 (a), Fab ICR62 (b) and scFv ICR62 (c).
This indicates an anti-idiotypic specificity, * Prebleed; 1, dayl4;
*, day 28.
but also for diagnostic and therapeutic applications in cancer
(for review see Modjtahedi and Dean, 1994). Several of the
mouse antibodies have undergone clinical evaluation in phase
I and phase II studies in patients with head and neck, lung or
brain cancers including MAb EGFR1 (Soo et al., 1987;
Kalofonos et al., 1989), MAbs 225 and 528 (Divigi et al.,
1991; Baselga et al., 1993), MAb 425 (EMD 55900 E Merck,
Brady et al., 1991; Magdelenat et al., 1991; Stasiecki et al.,
1993; Blizer et al., 1993; Dadparvar et al., 1994) and MAb
RG83852 (Perez-Soler et al., 1994). The aim of these studies,
in common with the one presented here, was to determine
whether treatment of cancer patients with anti-EGFR MAbs
produced life-threatening toxicities by their binding to EGFR
expressed by normal tissues, including liver and skin. The
results of these studies have shown that mouse antibodies to
the EGFR can be given safely to patients without untoward
toxicity. For example, Divigi et al. (1991) have treated
patients with advanced squamous cell carcinoma of the lung
with single doses of up to 300 mg of MAb 225, including
4 mg of "'In-labelled 225, without significant toxicity.
Furthermore, with doses of 40 mg or more they were able
to image presumed sites ofmetastasis greater than or equal to
1 cm in diameter.
Immunohistological examination of the biopsies from
metastatic sites, taken 24 h following ICR62 dosing,
demonstrated the localisation of MAb ICR62 to the tumour
cells. There appeared to be a dose-response effect in that the
depth of tumour penetration at a dose of 100 mg exceeded
that at 40 mg. The good tumour localisation of ICR62 in the
biopsies from patients treated with 100 mg of antibody was
encouraging. Indeed, the results of another study using the
mouse antibody RG83852 showed that localisation could
only be detected at doses of 400 mg m-2 or greater (Perez-
Soler et al., 1994). We selected MAb ICR62 for a phase I
clinical study since it was the most effective of a number of
2 4 8 16 32 64 128
1 2 4 8 16 32
Dilution of patient serum
64 128
Figure 5 Development ofhuman anti-rat antibodies in the serum
of patient number 11 following injection of 40mg of ICR62
shown by binding to intact ICR62 (a), Fab ICR62 (b) but not
scFv ICR62 (c). This indicates non-idiotypic (constant region)
specificity. M, Prebleed; [D, day 8; *, day 15.
rat MAbs we had generated against the human EGFR at
inducing the regression of xenografts of head and neck, vulva
and breast carcinomas grown in athymic mice (Modjtahedi et
al., 1993b, 1994; Dean et al., 1994).
In the present study, the results of the immunohistological
investigation showed that the cells adjacent to the vasculature
were strongly stained. This tumour cell population is likely to
have the highest proliferation index and any antiproliferative/
pro-differentiation effect here may be therapeutically sig-
nificant. This study has shown that MAb ICR62 can be given
safely to cancer patients at doses up to 100 mg producing
only mild toxicity. This trial was not designed to test the anti-
tumour activity of this agent.
The maintainance of receptor blockade may require
repeated treatment with antibody. Certainly, our experience
using xenograft models (Modjtahedi et al., 1993b, 1994)
points to the need to maintain sufficiently high blood levels
for long enough to (a) block EGFR function, (b) recruit to
the tumour and activate host effector cells and (c) induce
terminal differentiation. The limited data on the serum half-
life of ICR62 obtained in this investigation indicate that free
ICR62 was present 2-3 days post treatment and therefore
suggest that twice weekly doses of 100 mg may be sufficient
to maintain a high enough level of this antibody for
therapeutic activity. In the present investigation we were
able to biopsy metastatic sites at only a single early time
point so we have no information concerning the stability of
the antibody at the tumour cell surface or of the effects of
treatment on the recruitment and activation of host immune
effector cells. Such a study will form part of the next clinical
trial, in which we propose to investigate the potential
therapeutic effect of multiple treatments with ICR62.
Just 4 of the 20 patients developed HARA following a
single dose of MAb ICR62. Of these, only two were directed
against the idiotype of ICR62. These results suggest that
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MAb ICR62 is not as immunogenic as the mouse antibodies
to EGFR previously used in clinical studies. For example,
Divigi et al. (1991) found all 19 lung cancer patients treated
with a single dose of 1-300mg of MAb 225 developed
human anti-mouse antibodies. Stasieki et al. (1993) have also
found that a single infusion or multiple infusions at monthly
intervals of MAb EMD 55900 in glioma patients elicited
human anti-mouse antibodies. On the other hand, these
authors reported that following multiple infusions of glioma
patients with MAb EMD 55900 at shorter intervals (three
times per week, during 4 weeks or longer), human anti-mouse
antibodies were not detectable in the sera of these patients
(Stasiecki et al., 1993). In another encouraging clinical trial
reported recently, Riethmuller et al. (1994) have shown that
adjuvant treatment of 189 patients (Dukes' C colorectal
cancer) with 500 mg of mouse antibody 17-lA followed by
four 100 mg infusions at monthly intervals induced HAMA
responses in 80% of treated patients. However despite this,
the treatment schedule reduced the overall 5 year death rate
by 30% and decreased the recurrence rate by 27%. If HARA
developed following repeated doses of ICR62 and compro-
mised potential therapeutic effects due to rapid clearance, this
problem may be reduced by use of either chimaeric or
humanised versions of the antibodies. Alternatively, we have
the benefit of a variety of EGFR MAbs, which recognise
different epitopes on the EGFR and are of different isotypes,
that could be used for second and subsequent treatments
(Modjtahedi and Dean, 1994).
In summary, the results of this phase I clinical study with
the limited amounts of MAb ICR62 available have indicated
that MAb ICR62, which acts as an EGF, TGF-z and HB-
EGF antagonist, (a) can be administered safely to patients
with squamous cell carcinoma; (b) localises efficiently to
metastatic sites; and (c) may therefore have potential for the
treatment of the significant number of cancer patients whose
tumours overexpress the EGF receptor. A further clinical
study is planned using higher doses of MAb ICR62 given
either singly or as multiple doses.
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